



Patient Wallet Card

Tell any healthcare provider that sees you that you are being treated with YESCARTA® or TECARTUS®.

**SHOW THIS CARD if you go to the emergency room
or see any physician.**

You should plan to stay close to a healthcare facility for at least two weeks after getting YESCARTA or TECARTUS.

Please see Important Facts of [Yescarta](#) and [Tecartus](#), including **IMPORTANT WARNINGS**.

Important Information for Healthcare Providers

Name of treating oncologist: _____

Office phone: _____

After-hours phone: _____

Kite CAR T product administered:

☐ YESCARTA®

☐ TECARTUS®

Date of Kite CAR T infusion: _____

- This patient has received a CD19-directed genetically modified autologous T-cell immunotherapy (CAR T).

- **CAR T therapy can cause cytokine release syndrome (CRS) and neurologic toxicities, which may be fatal or life threatening. CRS may involve any organ system**



- **Contact the patient's oncologist immediately for further information**

For more information, please visit
www.yescarta.com or www.tecartus.com.



www.yescarta.com



www.tecartus.com

Patient Information

YESCARTA® or TECARTUS® may cause side effects that are life-threatening and can lead to death.

Call or see your oncologist or get emergency help **RIGHT AWAY** if you have any of **these symptoms**:

- Fever (100.4°F/38°C or higher)
- Difficulty breathing
- Chills or shaking chills
- Confusion
- Dizziness or lightheadedness
- Severe nausea, vomiting, or diarrhea
- Fast or irregular heartbeat
- Severe fatigue or weakness

YESCARTA, the Yescarta Logo, TECARTUS, the Tecartus Logo, KITE, and the Kite Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.

© 2025 Kite Pharma, Inc. All rights reserved. | US-PTF-00105 07/2025

